| 06th week of 2014 patent applcation highlights part 57 |
| Patent application number | Title | Published |
|---|
| 20140039001 | NOVEL SALTS OF 6-HETEROCYCLE SUBSTITUTED HEXAHYDROPHENANTHRIDINE DERIVATIVES - Disclosed herein are salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions. | 2014-02-06 |
| 20140039002 | SOLID FORMS OF A PHARMACEUTICALLY ACTIVE SUBSTANCE - The present invention provides solid forms of the compound of formula 1 and pharmaceutical uses thereof. (I) | 2014-02-06 |
| 20140039003 | TREATMENT OF GLAUCOMA - A method is provided for treating patients suffering from elevated intraocular pressure or fluctuation in intraocular pressure, including for example glaucoma patients. The method comprises administering to the patient an inhibitor of orexin activity in an amount sufficient to reduce intraocular pressure or intraocular pressure fluctuation in one or both eyes of the patient. | 2014-02-06 |
| 20140039004 | METHOD OF TREATING OF GASTROESOPHAGEAL REFLUX DISEASE - The development of agents for gastroesophageal reflux disease, in which existing treatment is not effective, is strongly demanded. An object of the present invention is to provide an agent for preventing or relapse-preventing, treating or ameliorating such gastroesophageal reflux disease. 4-[({6-[Isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof is effective in the prevention or relapse prevention, treatment or amelioration of gastroesophageal reflux disease. | 2014-02-06 |
| 20140039005 | NOVEL REBAMIPIDE COMPLEXES AND COCRYSTALS - New rebamipide complexes and new rebamipide cocrystals are disclosed, specifically a 1:1 rebamipide nicotinamide complex, a 1:1 rebamipide nicotinamide cocrystal, a 1:1 rebamipide 2,4-dihydroxybenzolc acid complex, and a 1:1 rebamipide 2,4-dihydroxybenzoic acid cocrystal. Pharmaceutical compositions containing a rebamipide complex or cocrystal of the invention and a pharmaceutically acceptable carrier and methods of treatment are also disclosed. | 2014-02-06 |
| 20140039006 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors - Tetrahydroquinoline derivatives, pharmaceutical compositions containing such compounds and to their use in therapy. | 2014-02-06 |
| 20140039007 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS - The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR). | 2014-02-06 |
| 20140039008 | METHODS FOR THE ADMINISTRATION OF ILOPERIDONE - The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms. | 2014-02-06 |
| 20140039009 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formulas (I), (VII) and (XI): | 2014-02-06 |
| 20140039010 | PHARMACEUTICAL COMPOSITION FOR TREATING AGING-ASSOCIATED DISEASES, CONTAINING PROGERIN EXPRESSION INHIBITOR AS ACTIVE INGREDIENT, AND SCREENING METHOD OF SAID PROGERIN EXPRESSION INHIBITOR - Disclosed are a method for treating an aging-related disease and a method for screening a therapeutic agent for an aging-related disease. The method for treating an aging-related disease includes administering to a subject a progerin expression inhibitor as an active ingredient. The method for screening a therapeutic agent for an aging-related disease includes selecting a candidate drug inhibitory of progerin expression. | 2014-02-06 |
| 20140039011 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA - The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes. | 2014-02-06 |
| 20140039012 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (II) | 2014-02-06 |
| 20140039013 | Composition for Inhibition of Insect Host Sensing - The present invention provide chemical modulators of insect olfactory receptors. In particular, compounds and compositions are provided that can inhibit host targeting functions in insects such as mosquitoes. Method of employing such agents, and articles incorporating the same, are also provided. | 2014-02-06 |
| 20140039014 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS - Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form. | 2014-02-06 |
| 20140039015 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition. | 2014-02-06 |
| 20140039016 | METHOD OF EMPLOYING ENHANCED PENETRATION OF WOOD PRESERVATIVES TO PROTECT WOOD AND A RELATED SOLUTION - A method of protecting wood through enhanced penetration of wood preservatives includes providing a solution including (a) at least one amine oxide, (b) at least one organic wood preservative and (c) a non-borate buffering based agent. The solution has a pH of 5 to 12.4 and preferably about 7 to 10. The solution is applied to the surface of the wood after which, with or without intervening storage, the materials are activated to effect enhanced penetration of the organic wood preservative into the wood. One may effect application at a solution temperature of about 30° C. to 75° C. and preferably about 50° C. to 60° C. to effect activation at a higher temperature and high relative humidity. In a preferred practice, the wood may be heated before and/or after application of the solution. The solution is also disclosed as a product. | 2014-02-06 |
| 20140039017 | THERAPEUTIC COMBINATION - This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans. | 2014-02-06 |
| 20140039018 | MYCOTOXIN ACCUMULATION INHIBITION METHOD AND MYCOTOXIN ACCUMULATION INHIBITOR - An fungicide capable of inhibiting the accumulation of the mycotoxin in a crop effectively and a mycotoxin accumulation inhibition method using said fungicide are provided. The mycotoxin accumulation inhibition method according to the invention is a mycotoxin accumulation inhibition method for inhibiting the accumulation of the mycotoxin in a grain after cropping comprising a first fungicide treatment step for treating the cereal plant after the flowering stage with a fungicide containing metconazole as an active ingredient. | 2014-02-06 |
| 20140039019 | Methods of Using Ryanodine Antagonists in Treating Neural Injury - The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a ryanodine antagonist, e.g. dantrolene, to inhibit or prevent nerve cell injury or death. | 2014-02-06 |
| 20140039020 | Oligomer-Containing Hydantoin Compounds - The invention relates to (among other things) oligomer-containing hydantoin compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer. | 2014-02-06 |
| 20140039021 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2014-02-06 |
| 20140039022 | MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIA MODULATOR - Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I: | 2014-02-06 |
| 20140039023 | SOLID GERMICIDAL COMPOSITION AND DISINFECTION METHOD - A solid germicidal composition containing a compound of the formula (I), a carbonate compound and an organic acid with a solubility in water at 20° C. of 0.25 to 35%: | 2014-02-06 |
| 20140039025 | Substituted Imidazole Derivatives and Methods of Use Thereof - The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. | 2014-02-06 |
| 20140039026 | POLYMORPHS AND AMORPHOUS FORMS OF 5-AMINO-1-[2,6-DICHLORO-4-(TRIFLUOROMETHYL)PHENYL]-4-[(TRIFLUOROMETHYL)SU- LFINYL]-1H-PYRAZOLE-3-CARBONITRILE - The present invention relates to novel crystalline polymorphs, solvate pseudomorphs and amorphous form of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile (fipronil). The present invention also provides methods for preparing the novel polymorphs, pseudomorphs and amorphous form, as well as insecticidal or pesticidal compositions comprising same, and methods of use thereof as pesticidal agents. | 2014-02-06 |
| 20140039027 | USE OF SDHI FUNGICIDES ON CONVENTIONALLY BRED ASR-TOLERANT, STEM CANKER RESISTANT AND/OR FROG-EYE LEAF SPOT RESISTANT SOYBEAN VARIETIES - The present invention relates to a method for controlling Asian soybean rust (ASR) of a conventionally bred ASR-tolerant, Stem canker resistant and/or Frog-eye leaf spot resistant soybean variety comprising the application of a succinate dehydrogenase inhibitor (SDHI) fungicide to said plant, plant propagation material, or at its locus of growth. | 2014-02-06 |
| 20140039028 | TRANSDERMAL FORMULATION CONTAINING COX INHIBITORS - Disclosed are gel compositions suitable for the topical administration of an active compound having poor solubility and skin penetration, for example, of a COX-2 inhibitor compounds, processes of preparation thereof and methods of use thereof for the treatment of indications treatable by the active compound. | 2014-02-06 |
| 20140039029 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS - The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals. | 2014-02-06 |
| 20140039030 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES - The invention relates to (among other things) polymer-des-ethyl sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over des-ethyl sunitinib in unconjugated form. | 2014-02-06 |
| 20140039031 | PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-B-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS - The present disclosure is directed to compositions and methods for formulating a pharmaceutical dosage form by forming a composition comprising acetyl-11-keto-β-boswellic acid, diindolylmethane, or curcumin with one or more pharmaceutically acceptable excipients for enhanced solubility to increase bioavailability and improve therapeutic efficacy. The composition can be processed by thermo-kinetic compounding along with conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding. | 2014-02-06 |
| 20140039032 | LIPID NANO PARTICLES COMPRISING CATIONIC LIPID FOR DRUG DELIVERY SYSTEM - The present invention provides a lipid nano-particles, which allow nucleic acids to be easily introduced into cells, comprising a cationic lipid represented by formula (I)
| 2014-02-06 |
| 20140039033 | NOVEL PANCREATIC CANCER BIOMARKER USING THE CHARACTERISTICS OF PANCREATIC CANCER STEM CELLS, AND USE THEREOF - The present invention relates to a novel molecular marker for pancreatic cancer stem cells and pancreatic cancer, to a marker detection method, and to a screening method. The present invention is a marker discovered from the cell lines of pancreatic cancer, wherein the marker may detect pancreatic cancer, in particular early pancreatic cancer, through the detection of a pancreatic cancer stem cell marker. In addition, the marker of the present invention may enable an accurate diagnosis and prognosis analysis of pancreatic cancer. | 2014-02-06 |
| 20140039034 | COMPOSITION FOR SUPPRESSING EXPRESSION OF TARGET GENE - The present invention provides a composition that comprises a lipidparticle encapsulating a double-stranded nucleic acid molecule,
| 2014-02-06 |
| 20140039035 | COMPOSITIONS AND METHODS FOR TREATING OBESITY - The present invention relates to the field of obesity. More specifically, the present invention provides methods and compositions useful in treating obesity and obesity-associated conditions. In a specific embodiment, a method for treating obesity comprises administering an effective amount of an agent that inhib its expression of neuropeptide Y (NPY). In another embodiment, the present invention provides a recombinant nucleic acid construct comprising a nucleic acid sequence encoding an oligonucleic acid, wherein the oligonucleic acid comprises at least one sequence substantially complementary to at least a part of the neuropeptide Y (NPY) gene or transcript thereof, and wherein the oligonucleic acid inhibits or reduces the expression of NPY. | 2014-02-06 |
| 20140039036 | Methods for Identifying Subjects with a Genetic Risk for Developing IgA Nephropathy - Seven protective alleles for IgA nephropathy have been discovered that can be identified by analyzing a DNA sample for seven respective SNPs. A method is provided for identifying and treating subjects at risk of developing IgA neuropathy based on a new seven-SNP genetic risk score. Also provided are screening methods to identify compounds that bind to and reduce the expression or biological activity of a either CFHR1 or CFHR3. | 2014-02-06 |
| 20140039037 | ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES, THE HCHWA-D MUTATION, AND TRINUCLEOTIDE REPEAT EXPANSIONS - Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA. | 2014-02-06 |
| 20140039038 | MULTI-CONJUGATE OF SIRNA AND PREPARING METHOD THEREOF - The present invention relates to a multi-conjugate of small interfering RNA (siRNA) and a preparing method of the same, more precisely a multi-conjugate of siRNA prepared by direct binding of double stranded sense/antisense siRNA monomers or indirect covalent bonding mediated by a cross-linking agent or a polymer, and a preparing method of the same. The preparing method of a siRNA multi-conjugate of the present invention is characterized by simple and efficient reaction and thereby the prepared siRNA multi-conjugate of the present invention has high molecular weight multiple times the conventional siRNA, so that it has high negative charge density, suggesting that it has excellent ionic interaction with a cationic gene carrier and high gene delivery efficiency. | 2014-02-06 |
| 20140039039 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 2014-02-06 |
| 20140039040 | ANALGESIC METHOD - An analgesic medication includes an oligonucleotide being a double strand RNA comprising 18 to 70 base pairs, and a pharmaceutical acceptable vehicle for delivering the said oligonucleotide into cells, wherein a dosage of the oligonucleotide in the analgesic is 50 μg to 200 μg/kg per time, and the pharmaceutical acceptable vehicle is selected from a group of polyethyleneimine, lipofectamine and iFect. | 2014-02-06 |
| 20140039041 | FILIP1L COMPOSITIONS AND METHODS FOR TREATING CANCER - A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth. | 2014-02-06 |
| 20140039042 | BISPECIFIC APTAMERS MEDIATING TUMOUR CELL LYSIS - Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer. | 2014-02-06 |
| 20140039043 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL - The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders. | 2014-02-06 |
| 20140039044 | Hydroxylated Polymethoxyflavone Compositions - Provided herein are compositions enriched in polyhydroxylated polymethoxyflavones useful as dietary supplements, food additives, pharmaceutical compositions, nutraceutical compositions and cosmetic compositions. | 2014-02-06 |
| 20140039045 | COMPOSITION OF MONOTERPENOIDS HAVING BACTERICIDAL PROPERTIES - A composition having bactericidal properties comprising; (a) 30%-80% of at least one compound having the formula (I) and (b) 10% to 40% of at least one compound of formula (II) | 2014-02-06 |
| 20140039046 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 2014-02-06 |
| 20140039047 | METHODS FOR REGULATING SIRTUIN GENE EXPRESSION - The invention provides methods useful for regulating sirtuin gene expression, mimicking caloric restriction, preventing and treating Alzheimer's disease, increasing longevity and retarding aging in an animal. The methods comprise administering one or more isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day. | 2014-02-06 |
| 20140039048 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES - Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions. | 2014-02-06 |
| 20140039049 | COMPOSITION CONTAINING SCIRPUSIN B, AND PROCESS FOR PRODUCING COMPOSITION CONTAINING SCIRPUSIN B - Provided are: a composition containing scirpusin B, which is a composition derived from a natural material and contains scirpusin B at a high content; and a process for producing the composition containing scirpusin B.A composition containing scirpusin B is produced by the extraction from a passion fruit seed. In the extraction of scirpusin B, the passion fruit seed is crushed, and subsequently at least one solvent selected from a hydrous alcohol solvent and a hydrous ketone solvent is added to the crushed product to thereby extract scirpusin B into the solvent. | 2014-02-06 |
| 20140039050 | METHOD FOR PREVENTING BACTERIAL INFECTION IN A FERMENTATION PROCESS - The present invention relates to an improved process for fermenting a sugar-containing material and an improved method for preventing bacterial infection in a fermentation process by using performic acid. The fermentation process is primarily the fermentation of sugar-containing material, for instance sugarcane, into ethanol. The present invention further relates to the manufacture of ethanol and the ethanol so obtained. | 2014-02-06 |
| 20140039051 | Cleaning and disinfection agent for medical instruments - The invention relates to a cleaner and/or disinfectant for medical and/or surgical elements and apparatuses which is formulated as a powder. It comprises at least one peroxide, at least one acylating agent for releasing peracetic acid from the peroxide in aqueous solution, and also at least one nonionic surfactant. According to the invention, it is provided that it comprises agents for adjusting a pH of a 2% strength aqueous solution to pH 7.5 to 9 and is formulated as granules, where peroxide and/or acylating agent are coated with nonionic surfactant. | 2014-02-06 |
| 20140039052 | FORMULATIONS OF LIPOPHILIC BIOACTIVE MOLECULES - This invention provides aqueous and non-aqueous clear formulations including at least one lipophilic bioactive molecules and an amphiphilic solubilizing agent. Exemplary aqueous formulations include a water-soluble reducing agent, which diminishes or prevents chemical degradation of the lipophilic bioactive molecule. The invention also provides methods of using the formulations of the invention. For example, the invention provides beverages including the formulations of the invention. The invention further provides methods of making the formulations and beverages. | 2014-02-06 |
| 20140039053 | THERAPEUTIC AGENT FOR DIASTOLIC CONGESTIVE HEART FAILURE - The present invention provides a pharmaceutical composition for the treatment of diastolic congestive heart failure containing at least one active ingredient selected from the group consisting of icosapentaenoic acid, a pharmaceutically acceptable salt thereof, and an ester thereof. | 2014-02-06 |
| 20140039054 | ORAL COMBINATION DRUG FORMULATION COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND A COMPLEMENTARY LOW DOSE OF TRANEXAMIC ACID FOR THE TREATMENT OF MENSTRUAL PAIN ACCOMPANIED WITH EXCESSIVE MENSTRUAL BLOOD LOSS - A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 50 mg to 425 mg per oral combination drug formulation. | 2014-02-06 |
| 20140039055 | Topical Glutathione Formulations For Menopausal Skin - Topical compositions to address menopausal skin conditions include an effective amount of S-acyl glutathione derivative and a carrier. Methods for addressing menopausal skin conditions include applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C | 2014-02-06 |
| 20140039056 | BROMFENAC ORGANIC SALTS AND PREPARATION METHOD, COMPOSITION AND USE THEREOF - Provided are bromfenac organic salts and preparation method, composition and use thereof. The bromfenac organic salt has the structure as shown in the following Formula I, wherein A represents an organic base. Also provided are a method for the preparation of the bromfenac organic salt, a composition comprising the bromfenac organic salts, a use of the bromfenac organic salts or the composition thereof in manufacture of a medicament for treatment and/or prophylaxis of an inflammation or for analgesia, and a method for treatment and/or prophylaxis of an inflammation or for analgesia. | 2014-02-06 |
| 20140039057 | Compositions - An ingestible particulate composition including at least one compound selected from the group consisting of 2,4-dichlorobenzyl alcohol, amylmetacresol, cetylpyridinium chloride, hexitidine, hexylresorcinol, flurbiprofen, lidocaine, benzocaine, ibuprofen, paracetamol, pectin, menthol, and benzydamine and one or more bioadhesive materials. Resulting particulate compositions have excellent flow characteristics, dust suppression, organoleptic properties and stability. They are highly suitable for administration direction into a patient's mouth, and ingested to alleviate the symptoms of a sore throat. | 2014-02-06 |
| 20140039058 | OPHTHALMIC SOLUTION - The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient. | 2014-02-06 |
| 20140039059 | USE OF HISTONE DEACETYLASE INHIBITORS FOR THE CARE OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE SYNDROMES - The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient. | 2014-02-06 |
| 20140039060 | TREATMENT OF CELL PROLIFERATIVE DISORDERS - The invention relates to compounds and their use in treating cell proliferative disorders, more specifically Syk tyrosine kinase-mediated disorders. | 2014-02-06 |
| 20140039061 | HYALURONIC ACID COMPOSITION - An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and a method of manufacturing such a composition. | 2014-02-06 |
| 20140039062 | INJECTABLE DEVICE AND METHOD FOR SCULPTING, AUGMENTING OR CORRECTING FACIAL FEATURES SUCH AS THE CHIN - An injectable device useful for facial sculpting and correction of facial features, for example, for augmenting the chin in a human being is provided, the device being made of a composition comprising a hyaluronic acid crosslinked with a multifunctional polyethylene glycol (PEG)-based crosslinking agent. | 2014-02-06 |
| 20140039063 | LEUKOTRIENES AND ASTHMA EXACERBATION RISK - The invention provides methods for predicting the risk for a subject of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent as well as methods for reducing a subject's risk of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent. | 2014-02-06 |
| 20140039064 | USE OF GINGERONE OR DERIVATIVES THEREOF FOR REDUCING OR DELAYING THE SIGNS OF SKIN AGEING - Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing. The present invention relates to the cosmetic use of at least one compound of general formula (I): in which:—R | 2014-02-06 |
| 20140039065 | TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES - The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease. | 2014-02-06 |
| 20140039066 | FORMULATION FOR GRITTY FOAM DISPENSER - Disclosed herein are foamable gritty foam compositions that can suspend particulate mechanical scrubbers with particles sized from about 100 microns to about 800 microns that is capable of being foamed through a non-aerosol, or unpressurized pump dispenser. | 2014-02-06 |
| 20140039067 | FILAMENTOUS POLYMER PARTICLES AND USE THEREOF AS RHEOLOGY MODIFIERS - The invention relates to polymer particles in the form of filaments formed by block copolymers, as well as to the use thereof as rheology modifiers for aqueous or organic solutions. A first aspect of the invention relates to filamentous polymer particles having a length/diameter ratio greater than 100, said particles being formed by block copolymers synthesized by controlled radical emulsion polymerization in emulsion, performed using at least one hydrophobic monomer in the presence of a water-soluble marcoinitiator. The invention is characterized in that the filamentous particles are obtained in an aqueous medium for the synthesis of said block copolymers, performed by heating the reaction medium to a temperature of 60 to 120° C., the final block copolymer containing between 10 and 50 mol. % of the water-soluble macroinitiator and the hydrophobic monomer conversion rate being at least 50%. A second aspect of the invention relates to a method for modifying the rheology of an organic or aqueous solution using said filamentous polymer particle. | 2014-02-06 |
| 20140039068 | Drug Delivery Compositions and Methods - The present invention provides compositions and methods for the delivery of therapeutics to a cell or subject. | 2014-02-06 |
| 20140039069 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 2014-02-06 |
| 20140039070 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 2014-02-06 |
| 20140039071 | ISOPENTYL ESTERS FOR USE IN COSMETIC, DERMATOLOGICAL OR PHARMACEUTICAL COMPOSITIONS - The invention provides the esters of a mixture of 2-methyl-1-butanol and 3-methyl-1-butanol and the use thereof for producing formulations. | 2014-02-06 |
| 20140039072 | METHOD FOR PRODUCING VESICLES - Provided is a method for producing vesicles which comprise a lipid as a main component and which encapsulate a functional substance therein. The method includes the steps of (a) putting the functional substance, lipid and water in a cylindrical container; and (b) producing the vesicles encapsulating the functional substance in lipid vesicles which comprise the lipid as a major component and which encapsulate the functional substance therein, by kneading the contents of the container with simultaneous rotational movement of the container around its center axis together with revolutionary movement of the container about a predetermined axis of revolution. | 2014-02-06 |
| 20140039073 | TRANSITION METAL NANOCATALYST, METHOD FOR PREPARING THE SAME, AND PROCESS FOR FISCHER-TROPSCH SYNTHESIS USING THE SAME - The present invention discloses a transition metal nano-catalyst, a method for preparing the same, and a process for Fischer-Tropsch synthesis using the catalyst. The transition metal nano-catalyst comprises transition metal nanoparticles and polymer stabilizers, and the transition metal nanoparticles are dispersed in liquid media to form stable colloids. The transition metal nano-catalyst can be prepared by mixing and dispersing transition metal salts and polymer stabilizers in liquid media, and then reducing the transition metal salts with hydrogen at 100-200° C. The process for F-T synthesis using the nano-catalyst comprises contacting a reactant gas mixture comprising carbon monoxide and hydrogen with the catalyst and reacting. In addition, the transition metal nanoparticles have smaller diameter and narrower diameter distribution, which is beneficial to control product distribution. Meanwhile, the catalyst can be easily separated from hydrocarbon products and reused. | 2014-02-06 |
| 20140039074 | METHOD FOR RAPID PREPARATION OF SUITABLE [18F]FLUORIDE FOR NUCLEOPHILIC [18F]FLUORINATION - The invention generally relates to the preparation of | 2014-02-06 |
| 20140039075 | Photodegradable Polycaprolactone Fumarate Block Copolymers - A polycaprolactone fumarate copolymer useful as a material for a biocompatible scaffold for tissue engineering applications is disclosed. The copolymer includes at least one caprolactone unit, at least one fumarate unit, and at least one third unit selected from the group consisting of acrylate units and styrenic units. A linking moiety forms a link between the third unit and at least one caprolactone unit or at least one fumarate unit. The linking moiety can be photodegradable. In one form, the third unit includes at least one methyl methacrylate unit. The copolymer can be used to form the wall of a nerve conduit. | 2014-02-06 |
| 20140039076 | URETHANE FOAM MOLDED PRODUCT AND METHOD FOR PRODUCING THE SAME - To provide a urethane foam molded product having high thermal conductivity and electric insulation and a method for producing the same. A urethane foam molded product includes a base material made of a polyurethane foam and composite particles that are blended in the base material and oriented in a mutually connected state, in which each of the composite particles includes a thermally conductive particle made of a non-magnetic body, and a magnetic particle and an insulating inorganic particle that are adhered to the surface of the thermally conductive particle through a binder. A powder of the composite particles can be produced by stirring a powder raw material containing a powder of the thermally conductive particle, a powder of the magnetic particle, a powder of the insulating inorganic particle, and the binder using a stirring granulator. | 2014-02-06 |
| 20140039077 | Method For Producing Oxidation Discoloration Resistant Polyurethane Foam - A flexible polyurethane foam with improved resistance to discoloration from oxidation is disclosed. Such discoloration may be due to exposure to oxides of nitrogen, for example, the oxides commonly found in burnt gas fumes. The foam may be used for applications such as intimate apparel and other consumer products that need extended term color stability. The foam composition includes high levels of reactive and non-reactive phosphite esters that improve color stability without disadvantage to the foam's physical and aesthetic properties during and after production. | 2014-02-06 |
| 20140039078 | POLYURETHANE FOAMS FOR TRENCH BREAKER AND OTHER APPLICATIONS - The invention is directed to polyurethane foams which are flotation resistant with sufficient strength and density to provide stability and inhibit erosion at pipeline trench sites, and other uses, wherein at least 50% of the foam is open cell and has a density of approximately 1.3 lbs/ft | 2014-02-06 |
| 20140039079 | POROUS POLYMER MEMBRANE WITH COVALENT NETWORK STRUCTURE AND PRODUCTION METHOD THEREOF - The present disclosure provides a porous polymer membrane having a covalent network structure and a method for producing the same. The method includes: polymerizing a first monomer having four first functional groups oriented in a tetrahedral arrangement with a second monomer having at least two second functional groups to prepare porous organic framework nanoparticles; mixing the solution of the porous organic framework nanoparticles with a polymer; and applying the mixed solution to a substrate, followed by heating to form a polymer matrix containing the nanoparticles. According to the method, a polymer membrane with excellent chemical stability, heat resistance, durability and permeability can be produced through simple processes. Advantageously, the porous structure of the polymer membrane can be easily modified depending on intended applications of the polymer membrane. | 2014-02-06 |
| 20140039080 | RUBBER COMPOSITION, VULCANIZED RUBBER AND TIRE MANUFACTURED USING THE SAME - The present invention provides a rubber composition that may improve fracture resistance of the resulting tire while maintaining good drainage performance, and a tire using the same. The rubber composition includes: a rubber component; and a fiber made of a hydrophilic resin. The fiber is formed with a coating layer on its surface. The coating layer is made of a resin having affinity for the rubber component. | 2014-02-06 |
| 20140039081 | SULPHUR-CONTAINING THERMOPLASTIC POLYMERS - A process For the production of a thermoplastic polymer including carbon and sulphur in an atomic ration of C:S of at least 4 and at most 36 using thiol-ene addition polymerization, preferably with feedstocks obtained from renewable resources such as fatty acids from vegetable origin. The product is preferably aliphatic, meaning that at most 70% of the protons are present as aromatic hydrogen atoms and, if oxygen atoms are present in ester functions, the atomic ratio of the oxygen atoms present in ester functions relative to the number of sulphur atoms in the polymer is less than 1.0. The polymer may be used to produce a shaped article. | 2014-02-06 |
| 20140039082 | Enhanced Thermally Conductive Cushioning Foams by Addition of Metal Materials - Methods and combinations for making and using one or more thermally conductive cellular foam layers comprising flexible cellular foam and metallic material particulates, and said thermally-conductive cellular foam layers may be located on, under, or in cushioning foams and mattresses or placed between on, under, within, or between other layering substrates to increase the overall cooling capability of the composite. The thermally conductive foam may be used in mattresses, pillows, bedding products, medical cushioning foams, and similar materials used in bedding environments. | 2014-02-06 |
| 20140039083 | PRESSURE-SENSITIVE ADHESIVES WITH MIXED PHOTOCROSSLINKING SYSTEM - The present disclosure provides a method of providing an adhesive composition comprising the steps of combining crosslinkable composition including: a) a (meth)acryloyl monomer mixture with the b) photocrosslinking agent mixture, and irradiating with UVC radiation to polymerize and crosslink the composition. | 2014-02-06 |
| 20140039084 | SURFACE MODIFICATION METHOD AND SURFACE-MODIFIED ELASTIC BODY - The present invention aims to provide a surface modification method for a rubber vulcanizate or a thermoplastic elastomer, which can impart excellent sliding properties and excellent durability against repeated sliding motion and can allow the surface to maintain the sealing properties, without using expensive self-lubricating plastics. The present invention relates to a surface modification method for modifying a rubber vulcanizate or a thermoplastic elastomer as an object to be modified, the method including: step 1 of forming polymerization initiation points on the object to be modified; step 2 of radically polymerizing a monomer, starting from the polymerization initiation points, by irradiation with LED light at 300 nm to 400 nm to grow polymer chains on a surface of the object to be modified; and step 3 of esterifying, transesterifying or amidating side chains of the polymer chains. | 2014-02-06 |
| 20140039085 | DEGRADABLE THIOL-ENE POLYMERS - A thiol-ene polymeric material is disclosed. The material is produced by the photopolymerization of reactants having thiol and olefin moieties. The material can incorporate encapsulated components, including cells. Additionally, the material can be derivatized by reacting the polymeric material with components such as proteins. | 2014-02-06 |
| 20140039086 | CURABLE COLORED INKS FOR MAKING COLORED SILICONE - The present invention provides an actinically or thermally curable ink for making colored silicone hydrogel contact lenses. The ink of the invention comprises at least one colorant, a solvent and a binder polymer including ethylenically unsaturated groups and segments derived from at least one silicone-containing vinylic monomer or macromer. The ink of the invention is characterized by having capability to be cured actinically or thermally to form a colored coat on a silicone hydrogel contact lens, wherein the colored coat has good adhesion to the silicone hydrogel contact lens without being covalently attached to the lens material of the contact lens. The invention also provides methods for making colored silicone hydrogel contact lenses. | 2014-02-06 |
| 20140039087 | DENTAL COMPOSITION - Dental composition comprising a water-soluble polymerizable compound of the following formula (1): wherein A is a linear or branched linker group represented by the following formula (3), wherein the nitrogen atom of at least two of the termini forms an amide bond with an X moiety; wherein R′ represents a hydrogen atom or a substituted or unsubstituted aliphatic or cycloaliphatic hydrocarbon group, wherein each R may be the same or different L | 2014-02-06 |
| 20140039088 | DENTAL COMPOSITION - Dental composition comprising (i) a particulate filler; (ii) a polymerizable hydrolysis-stable compound of the following formula (1) AX | 2014-02-06 |
| 20140039089 | Compositions Containing Phosphonate Catalysts And Methods For The Preparation And Use Of The Compositions - A composition is capable of curing via condensation reaction. The composition uses a phosphonate condensation reaction catalyst. The phosphonate is used to replace conventional tin catalysts. The composition can react to form a gum, gel, or rubber. | 2014-02-06 |
| 20140039090 | PROCESS OF MAKING A STABLE AQUEOUS DISPERSION OF CONCENTRATED, FINELY DIVIDED PARTICLES OF A BIOCIDE - This invention provides a process of making a stable aqueous dispersion including concentrated, finely divided particles of a water insoluble biocide active, which comprises grinding the biocide in water in the presence of a non-ionic polymeric dispersant and optionally a co-dispersant, and compositions prepared by this process. | 2014-02-06 |
| 20140039091 | Interactive Coating for End Printing - Thermochromic coatings are improved by mixing thermochromic capsules with polymer resins in a manner that imparts shelf stability to flowable precursors that may be cured quickly using dodecylbenzenesulfonic acid and/or other acid catalysts to form relatively hard coatings that are capable of withstanding machine operations, such as the operations needed to make beverage can lids, bottle caps, pull tabs and the like. | 2014-02-06 |
| 20140039092 | Procedure summary of water-based polymer resin doped titanium dioxide nanotubes as application corrosion coating. - The present invention relates to the application of polymeric resins and TiO2 doped with polymeric resins as coatings for external metal surfaces for industrial use, by selecting the following metals: stainless steel, carbon steel and copper. Focuses specifically on the synthesis of a polymeric resin waterborne corrosion consisting of nano-structured polymer particles formed with two or more acrylic monomers, vinyl or styrenic a functionalizing agent and a crosslinking agent from 1.0 to 20% w each. Doping addition is made of the same polymeric resins, which are incorporated in nanotubes of titanium dioxide in concentrations ranging from 50 to 10,000 ppm. The polymeric resin is water based corrosion synthesized by emulsion polymerization techniques and is during the synthesis process is introduced nanotube loading of titanium dioxide, which allowing the dispersion in the polymer matrix. Polymer dispersions obtained in this way are used as anti-corrosion coatings 100% water based. | 2014-02-06 |
| 20140039093 | ALKYD-BASED COATING COMPOSITION - The present invention relates to a coating composition comprising: a) silanized colloidal silica particles; b) alkyd-containing binder; c) a carrier fluid, wherein the coating composition is essentially free from a cobalt-based drier. The present invention also relates to a method of producing a coating composition and the use of such coating composition for coating of a substrate. | 2014-02-06 |
| 20140039094 | EPOXY RESIN COMPOSITION, AND PREPREG AND PRINTED CIRCUIT BOARD USING THE SAME - Disclosed is an epoxy resin composition for printed circuit board, which includes (A) an epoxy resin; (B) a curing agent; (C) an inorganic filler including manganese oxide; and (D) a curing accelerator. | 2014-02-06 |
| 20140039095 | HIGH IMPACT POLYSTYRENE FLAME RETARDED COMPOSITIONS - The invention relates to a polymer composition comprising high impact polystyrene (HIPS) and a combination of flame retardants which are brominated epoxy oligomers and polymers. A process for preparing the HIPS composition through a masterbatch route and a masterbatch composition which contains the flame retardants are also disclosed. | 2014-02-06 |
| 20140039096 | BIOLOGICALLY DEGRADABLE POLYMERIC COMPOSITION WITH HIGH DEFORMABILITY - The invention concerns a biologically degradable polymeric composition containing 5 to 95 wt % of polyhy droxyalkanoate and 95 to 5 wt % of polylactic acid or lactide with addition of 2 to 67 parts of plasticizer or mixture of plasticizers per 100 parts of the polymeric blend. The invention covers also composition containing 0.05 to 5 wt % of a reactive additive. Plasticizers are selected from chemicals, such as esters of citric acid, esters of glycerol, esters of phosphoric acid, esters of sebacic acid and other liquid organic low-molecular polyesters. The reactive additive is selected from a group of chemicals such as acrylic polymers, epoxidized acrylic polymers, diisocyanates and their derivatives, epoxidized oils, oligomeric copolymers of various monomers with glycidyl methacrylate and other species. | 2014-02-06 |
| 20140039097 | SELF-CONSOLIDATING CONCRETE (SCC) MIXTURE HAVING A COMPRESSIVE STRENGTH OF AT LEAST 25 MPA AT 28 DAYS OF AGE - The present disclosure describes a self-consolidating concrete (SCC) mixture having a compressive strength of at least 25 MPa at 28 days of age. In accordance with one embodiment, there is provided an SCC mixture, comprising: a mixture of coarse aggregate (CA), fine aggregate (FA), very fine aggregate (VFA), Portland cement or Portland limestone cement, an ASTM C494 Type F polycarboxylate ether high range water reducer, and water, wherein the VFA has a particle size distribution in which 95% to 100% passes a 2.5 mm sieve and in which 20% to 100% passes a 75 μm sieve. | 2014-02-06 |
| 20140039098 | COPOLYMERS HAVING GEM-BISPHOSPHONATE GROUPINGS - The invention relates to a copolymer comprising a main hydrocarbon chain and side groups including carboxylic groups and polyoxyalkylate groups, characterized in that it further includes gem-bisphosphonate groups, an admixture for suspensions of mineral particles comprising said copolymer and to a method for preparing said copolymer. | 2014-02-06 |
| 20140039099 | POLYMER BLEND COMPOSITIONS - Thermoplastic compositions having miscible and compatible immiscible polymer blends are disclosed. The miscible polymer blends have a single glass transition temperature. The compatible polymer blends have two glass transition temperatures. | 2014-02-06 |
| 20140039100 | BI - OR TRICYCLIC STERICALLY HINDERED ALKOXYAMINES AND PROCESS FOR THEIR PREPARATION - The instant invention pertains to novel bi- or tricyclic sterically hindered alkoxyamines, their precursors, a process for their preparation and their use as light stabilizers for polymers or coatings, as flame retardants, as peroxide substitutes (rheology modifiers) or carbon radical scavengers. | 2014-02-06 |
| 20140039101 | Synergistic Emulsion Polymer Formulation and Aqueous Coating/ Paint Compositions Involving the Same - A synergistic emulsion polymer formulation adapted for facilitating achieving desired open time or wet edge time of any aqueous coating/paint composition on application to thus result in improved workability of the coating/paint composition. The synergistic emulsion polymer formulation and the coating/paint composition including the same comprises a latex polymer derived from copolymerization of mono-ethylenically unsaturated monomers. This in combination with select sorbitol ethoxylates esterified with fatty acids as an ingredient in the formulation/composition favors the slowing down of water evaporation from the composition considerably so that it remains amenable to touch up even after several minutes of application. | 2014-02-06 |
